AVBP Company Profile and Key Details

AVBP has shown sold momentum, gaining 8.9% over the past week and 14.1% over the past quarter, though year-to-date performance is up 10.64%. Short-term trend indicators are bearishly aligned (SMA20 3.26%, SMA50 5.34%, SMA200 11.15%). The stock’s 14-day RSI is 56.48 (neutral), while the ATR of 1.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.76% below its high and over 50.16% above its low. Average 10-day trading volume of 427.66 thousand shares is below the 3-month average of 516.11 thousand, indicating normal recent market interest.

ArriVent BioPharma, Inc. has 49.31 million shares outstanding. The public float is 32.11 million shares, elevated short interest at 18.39% of float. This equals 8.05 million shares. The short ratio is 15.41 days. Institutional investors hold 97.72% of the float. Insiders own 1.63%. HILLHOUSE INVESTMENT MANAGEMENT, LTD. holds 3.93 million shares, HEALY JAMES has 1.70 million shares and GORDON CARL L has 1.51 million shares.

ArriVent BioPharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.18. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of -5.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $31.00. The high target offers 74.22% upside. The low target suggests 8.01% downside. The mean target is $42.36. This offers 47.6% upside. ArriVent BioPharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 12, 2026, missed forecasts by 6.35%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include 187.88% in May 12, 2025.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) closed at $28.70 USD, losing -$1.09 (-3.66%) from the previous close of $29.79. The stock is currently mid-range between its 52-week high and low $17.00 and $35.83. With a market capitalization of about $1.34 billion, ArriVent BioPharma, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 519.11 thousand shares, in line with its 52-week average. Headquartered in Newtown Square, PA, ArriVent BioPharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zhengbin Yao, the company employs approximately 77 people and listed since January 26, 2024. ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

ArriVent BioPharma, Inc. trades at a P/E ratio of -7.8, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.72 trading at moderately above to book value. The P/FCF stands at -9.03, also below market averages.

Our AI price prediction model suggests that ArriVent BioPharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.23%, with price expected at $29.34 by September 24, 2026, within a range of $28.48 to $30.23 3-Month Outlook: Projected rise of 69.65%, reaching $48.69 by December 08, 2026, with a range of $47.17 to $50.51. 1-Year Outlook: Projected gain of 12.3%, with price at $32.23 by September 10, 2027, within a range of $30.17 to $33.46.

ArriVent BioPharma, Inc. (NASDAQ:AVBP) shares are up 10.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ArriVent BioPharma, Inc. trading at a premium to the broader market with a P/E of -7.8. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $39.70, suggesting 38.33% upside. Our AI forecast model points to short-term strength (2.23% over two weeks), a medium-term rise (69.65% over three months), and a longer-term gain (12.3% over one year), with expected trading ranges indicating moderate volatility.